Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster | Vaccines

Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster

Related Keywords

United States ,India ,Netherlands ,Groningen ,Todd Zion ,Schelto Kruijff ,Johnson Janssen ,Akston Biosciences ,Pfizer ,Astrazeneca ,Clinical Research Organization ,University Medical Center Groningen ,I Akston Biosciences Corporation ,Rapid Cure Task Force ,Akston Biosciences Doses First Participants ,Emergency Use Authorization ,United Statesi May ,Akston Biosciences Corporation ,Receptor Binding Domain ,Cure Task Force ,Vaccine ,Immunotherapy ,Immune Therapy ,Desensitization ,Personalized Immunotherapy ,Ntigen ,Ellular ,Recombinant ,Protein ,Peptide ,Subunit ,Multivalent ,Cancer Vaccine ,